SCHEMBL2904789

SCHEMBL2904789

C[C@H](CO)NC(=O)c1cn(CCCNc2ccc([N+](=O)[O-])c(N)n2)cc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.48
GSK3A P49840 3/20 0.48
CDK1 P06493 2/20 0.44
CCNB2 O95067 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
CNR2 P34972 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
AHR P35869 1/20 0.33
SYK P43405 1/20 0.32
LMNA P02545 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
HSD11B1 P28845 1/20 0.32
FOLH1 Q04609 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12892551 1.00 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910831 1.00 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2908086 0.98 GSK3B (0.47) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910067 0.98 GSK3B (0.47) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2907240 0.93 GSK3B (0.40) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2913460 0.93 GSK3B (0.40) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2912215 0.93 GSK3B (0.42) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2905208 0.93 GSK3B (0.42) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2907075 0.93 GSK3B (0.47) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2903805 0.92 GSK3B (0.41) GSK3BGSK3ACDK1CCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537099-B1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-08-11 EP disclosed